Kinases in Diabetes
Thursday 11 November 2004
09:00 - 10:30 Registration and coffee/tea
Kinases in insulin signalling
Emmanuel Van Obberghen (Nice, France)
Establishing a therapeutic foothold in the signalling cascade during the age of the Torrent of Kinases
Alex Bridges (QuatRx Pharmaceuticals, USA)
12:00 - 13:30 Lunch and poster session
The AMP-activated protein kinase cascade: linking metabolic disease with cancer?
David Carling (Imperial College London, UK)
Regulation and function of the PDK1 kinase
Dario Alessi (Dundee, UK)
15:00 - 15:30 Coffee/tea break
Atypical PKCs in insulin action and insulin resistance
Robert Farese (Tampa, FL, USA)
Signal transduction in human skeletal muscle: identifying the defects in type 2 diabetes
Juleen Zierath (Karolinska Hospital, Stockholm, Sweden)
Modulation of insulin signalling by insulin sensitizers
Bei B Zhang (Merck Research Laboratories, Rahway, NJ, USA)
Insulin action on glucose uptake: identifying novel substrates for protein kinase B
Jeremy Tavaré (Bristol, UK)
10:30 - 11:00 Coffee/tea break
Small molecule glucokinase activators as novel anti-diabetic agents
Brendan Leighton (AstraZeneca, UK)
PDH kinase inhibitors: a novel therapy for Type 2 diabetes?
Rachel Mayers (AstraZeneca, UK)
12:30 - 14:00 Lunch and poster session
Map kinase in pancreatic beta cell function
Melanie Cobb (Texas, TX, USA)
Steven Shoelson (Harvard, MA, USA)